Business
Willow Biosciences Announces Cannabinoid Scale-Up and Expedited Path to Commercialization
Willow Biosciences Announces Cannabinoid Scale-Up and Expedited Path to Commercialization ...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n\n\n\nWillow Biosciences Announces Cannabinoid Scale-Up and Expedited Path to Commercialization\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, March 12, 2020\n\n\n\nCALGARY, March 12, 2020 /CNW/ - Willow Biosciences Inc. (\"Willow\" or  \"the Company\") (TSX: WLLW; OTCQB: CANSF), is pleased to announce that it has achieved its first major commercial milestone by delivering a proprietary cannabinoid-producing yeast strain to its scale-up development partner, Albany Molecular Research, Inc. (\"AMRI\") to begin the process of scaling up production to commercial volumes. \nWillow's successful yeast-strain engineering efforts have created multiple cannabinoid strains with promising properties that the Company will use as a basis for commercialization. The Company's skilled science team were able to reach this critical step ahead of its initial expectations and combined with its partnership with AMRI, the Company expects to reach its commercialization phase in the first half of 2021, six months sooner than originally expected.\n\"We are extremely pleased with the success of our scientists,\" said Trevor Peters, Willow's Chief Executive Officer. \"Their ability to create the yeast strain that will form the base of our future production ahead of expectations, is a testament to their skill and expertise. As we move into the scale-up phase of our development, our partnership with AMRI positions us for future success. AMRI has significant experience and substantial resources to support not only the technical development and implementation of our scale up, but also brings several other valuable strengths for commercial development, including regulatory and quality-control capabilities.\" \nWillow has started its initial development scale up-work in lab scale fermentation vessels with the goal of  reaching a 500 litre pilot scale demonstration by the fourth quarter of 2020. The scale-up process to reach pilot scale includes iterative strain development to increase the cannabinoid concentration of the yeast cell, fermentation optimiza...